Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Factor Xa or thrombin: is factor Xa a better target?

J Ansell1

  • 1Boston University School of Medicine, Boston, MA 02118, USA. jack.ansell@bmc.org

Journal of Thrombosis and Haemostasis : JTH
|August 1, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

It's time to improve antithrombotic therapy! A global perspective for antithrombotic stewardship.

European journal of internal medicine·2026
Same author

Safety of maintaining elective and emergency surgery during the COVID-19 pandemic with the introduction of a Protected Elective Surgical Unit (PESU): A cross-specialty evaluation of 30-day outcomes in 9,925 patients undergoing surgery in a University Health Board.

Surgery open science·2022
Same author

Paving the way for application of next generation risk assessment to safety decision-making for cosmetic ingredients.

Regulatory toxicology and pharmacology : RTP·2021
Same author

Variation in training requirements within general surgery: comparison of 23 countries.

BJS open·2021
Same author

Facing the Ethical Challenges: Consumer Involvement in COVID-19 Pandemic Research.

Journal of bioethical inquiry·2020
Same author

Safe management of surgical smoke in the age of COVID-19.

The British journal of surgery·2020

New oral anticoagulants targeting factor Xa (FXa) show promise over vitamin K antagonists. FXa inhibitors offer improved safety and effectiveness, potentially surpassing factor IIa inhibitors for thrombosis treatment.

Area of Science:

  • Pharmacology
  • Hematology
  • Thrombosis Research

Background:

  • Vitamin K antagonists (VKAs) have limitations in effectiveness and safety.
  • Oral anticoagulants targeting specific coagulation factors are under development.
  • Factor Xa (FXa) and factor IIa (FIIa) are key targets for new anticoagulants.

Purpose of the Study:

  • To evaluate the potential of direct FXa and FIIa inhibitors.
  • To compare the pharmacokinetic and pharmacodynamic properties of new anticoagulants versus VKAs.
  • To assess the evidence supporting FXa as a superior target for anticoagulation.

Main Methods:

  • Review of coagulation factor interaction theory.
  • Analysis of in vitro studies on coagulation inhibition.

Related Experiment Videos

  • Evaluation of clinical outcomes from FXa and FIIa inhibitor studies.
  • Comparison with existing anticoagulants like enoxaparin and fondaparinux.

    • Main Results:

    • FXa inhibition may be more effective than FIIa inhibition due to amplified coagulation.
    • Direct thrombin (FIIa) inhibitors show incomplete thrombin generation suppression and potential rebound hypercoagulability.
    • Early phase II results suggest FXa inhibitors are effective and safe across various doses.

    Conclusions:

    • Factor Xa represents a promising target for novel oral anticoagulants.
    • New FXa inhibitors may overcome limitations associated with VKAs and direct FIIa inhibitors.
    • Further clinical evaluation is warranted for FXa inhibitors in thrombosis management.